<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01479426</url>
  </required_header>
  <id_info>
    <org_study_id>LOTTE-MS-EFLA400</org_study_id>
    <nct_id>NCT01479426</nct_id>
  </id_info>
  <brief_title>A Trial to Evaluate the Efficacy and Safety of EFLA400 Korea Red Ginseng Extract on Sexual Function in Men With Erectile Dysfunction</brief_title>
  <official_title>Efficacy and Safety of EFLA400 Korea Red Ginseng Extract on Erectile Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chonbuk National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chonbuk National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Korea red ginseng has been used in maintaining vitality throughout the globally and
      metabolism and actions on neurologic, cardiovascular, and endocrinologic system are studied.
      KRG has been used in various ailment, and to prove its efficacy for erectile dysfunction an
      international study on contries other than Korean was performed. In the present study,
      subjects with borderline organic and psychogenic erectile dysfunction will be included. KRG
      will be give daily, and placebo will be give as control. Outcomes including libido, erection,
      sexual activity, and sexual satisfaction will be measured.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Among the three main lines of therapy for erectile dysfunction (ED), that is, oral therapy,
      self-injection therapy and penile prosthesis implantation, the first line therapy is always
      the first option. Despite the successful advent of sildenafil, the first effective oral agent
      for ED, further development of new drugs and phytochemical studies of widely known herbal
      plants are desirable. Furthermore, there seems to be a large population that prefers to use
      phytotherapies rather than pharmaceutical drugs for their health. Korean red ginseng, a
      phytotherapy plants, used frequently for ED. Ginseng is one of the most popular herbs in both
      Eastern and Western countries. It is known as a traditional Asian medicine for stimulation of
      sexual function and studies have shown the effects of ginseng on relaxation of penile corpus
      cavernous smooth muscle in many studies. In the present study, the investigators will be
      determined the real role of Korean red ginseng in the treatment of ED.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in EF(Erectile Function) Domain</measure>
    <time_frame>12 weeks</time_frame>
    <description>EF(erectile function, score 0-20) domain was measured in study visit 1(0 week) and visit 3(12 week).
The original index consists of 4 Questions. Individual question response is assigned a score of between 0 (worst) to 5 (best) and summed to form a score ranging from 0 (worst) to 20 (best).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in MSHQ (Male Sexual Health Questionnaire)</measure>
    <time_frame>12 weeks</time_frame>
    <description>MSHQ(Male Sexual Health Questionnaire) was measured in study visit 1(0 week) and visit 3(12 week).
The total MSHQ score (25 questions) ranges from 17-130, with higher scores indicating greater sexual function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GEAQ (Global Efficacy Assessment Question)</measure>
    <time_frame>after 12weeks of consumption</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Uroflowmetry(Max Flow Rate)</measure>
    <time_frame>12 weeks</time_frame>
    <description>uroflowmetry(max flow rate) was measured in study visit 1(0 week) and visit 3(12 week).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in IIEF(International Index of Erectile Function)-Total Domain</measure>
    <time_frame>12 weeks</time_frame>
    <description>IIEF(International Index of Erectile Function)-total domain(score range: 5-75) was measured in study visit 1(0 week) and visit 3(12 week).
IIEF includes 15 questions and addresses the 5 sub-domains of Erectile function, Intercourse satisfaction, Orgasm function, Sexual desire, and Overall satisfaction.
The IIEF-total domain is the sum of sub-domains. Lower scores indicate severe erectile dysfunction, while higher scores indicate less erectile dysfunction.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Healthy Subjects(Only Men)</condition>
  <arm_group>
    <arm_group_label>EFLA400(960mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo(960mg)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>EFLA400</intervention_name>
    <description>EFLA400(960mg/day)for 12 weeks</description>
    <arm_group_label>EFLA400(960mg)</arm_group_label>
    <other_name>EFLA400 Korean red ginseng</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo(960mg/day) for 12 weeks</description>
    <arm_group_label>Placebo(960mg)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  aged 17-70 years

          -  IIEF(International Index of Erectile Function)-5 scores ≤ 21 subjects.

        Exclusion Criteria:

          -  they had other neurologic or psychiatric disorder

          -  significant hepatic or renal function impairment (hepatic enzymes &gt;1.5 times the upper
             limit of normal and/or serum creatinine &gt;1.8 mg per 100 ml)

          -  hypertension (&gt;170/110 mm Hg), hypotension (&lt;90/50 mm Hg) or significant
             cardiovascular disease (unstable angina, coronary artery disease, myocardial
             infarction or myocardial revascularization).

          -  Peyronie's disease
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jong-Kwan Park, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonbuk National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Trial Center for Functional Foods; Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <state>Jeollabuk-do</state>
        <zip>560-822</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>November 16, 2011</study_first_submitted>
  <study_first_submitted_qc>November 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2011</study_first_posted>
  <results_first_submitted>July 26, 2012</results_first_submitted>
  <results_first_submitted_qc>August 21, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 23, 2019</results_first_posted>
  <last_update_submitted>August 21, 2019</last_update_submitted>
  <last_update_submitted_qc>August 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chonbuk National University Hospital</investigator_affiliation>
    <investigator_full_name>Soo-Wan Chae</investigator_full_name>
    <investigator_title>Clinical Trial Center for Functional Foods</investigator_title>
  </responsible_party>
  <keyword>Erectile dysfunction</keyword>
  <keyword>Korean Red Ginseng</keyword>
  <keyword>IIEF(International Index of Erectile Function)</keyword>
  <keyword>MSHQ(Male Sexual Health Questionnaire,)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited through local advertising and doctor referrals from hospital outpatients and general practice clinics.</recruitment_details>
      <pre_assignment_details>The criteria were an age from 19 to 70 years, IIEF(International Index of Erectile Function)-5 scores ≤ 21 subjects.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>EFLA400</title>
          <description>EFLA400(2times/day, 2capsules/day, 960mg/day) for 12weeks
EFLA400: Red Ginseng (90%) and Crataegus pinnatifida Bunge (10%) to high temperature (110 ~ 120 ˚ C) were reacted in the ginsenoside Rg3 increased by alcohol extraction after manufacture.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo(2times/day, 2capsules/day, 960mg/day) for 12weeks
Placebo : Amount and calorie of placebo are same with EFLA400</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>EFLA400(960mg)</title>
        </group>
        <group group_id="B2">
          <title>Placebo(960mg)</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="80"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.13" spread="6.65"/>
                    <measurement group_id="B2" value="59.70" spread="7.59"/>
                    <measurement group_id="B3" value="59.91" spread="7.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Changes in EF(Erectile Function) Domain</title>
        <description>EF(erectile function, score 0-20) domain was measured in study visit 1(0 week) and visit 3(12 week).
The original index consists of 4 Questions. Individual question response is assigned a score of between 0 (worst) to 5 (best) and summed to form a score ranging from 0 (worst) to 20 (best).</description>
        <time_frame>12 weeks</time_frame>
        <population>per protocol analysis</population>
        <group_list>
          <group group_id="O1">
            <title>EFLA400</title>
            <description>Oral intake EFLA400(960mg/day) for 12weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral intake placebo(960mg/day) for 12weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in EF(Erectile Function) Domain</title>
          <description>EF(erectile function, score 0-20) domain was measured in study visit 1(0 week) and visit 3(12 week).
The original index consists of 4 Questions. Individual question response is assigned a score of between 0 (worst) to 5 (best) and summed to form a score ranging from 0 (worst) to 20 (best).</description>
          <population>per protocol analysis</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.53" spread="4.33"/>
                    <measurement group_id="O2" value="12.89" spread="4.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.56" spread="4.92"/>
                    <measurement group_id="O2" value="16.46" spread="5.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in MSHQ (Male Sexual Health Questionnaire)</title>
        <description>MSHQ(Male Sexual Health Questionnaire) was measured in study visit 1(0 week) and visit 3(12 week).
The total MSHQ score (25 questions) ranges from 17-130, with higher scores indicating greater sexual function.</description>
        <time_frame>12 weeks</time_frame>
        <population>per protocol analysis</population>
        <group_list>
          <group group_id="O1">
            <title>EFLA400</title>
            <description>Oral intake EFLA400(960mg/day) for 12weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral intake placebo(960mg/day) for 12weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in MSHQ (Male Sexual Health Questionnaire)</title>
          <description>MSHQ(Male Sexual Health Questionnaire) was measured in study visit 1(0 week) and visit 3(12 week).
The total MSHQ score (25 questions) ranges from 17-130, with higher scores indicating greater sexual function.</description>
          <population>per protocol analysis</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.28" spread="12.98"/>
                    <measurement group_id="O2" value="71.62" spread="14.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.22" spread="17.34"/>
                    <measurement group_id="O2" value="83.81" spread="19.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GEAQ (Global Efficacy Assessment Question)</title>
        <time_frame>after 12weeks of consumption</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Uroflowmetry(Max Flow Rate)</title>
        <description>uroflowmetry(max flow rate) was measured in study visit 1(0 week) and visit 3(12 week).</description>
        <time_frame>12 weeks</time_frame>
        <population>per protocol analysis</population>
        <group_list>
          <group group_id="O1">
            <title>EFLA400</title>
            <description>Oral intake EFLA400(960mg/day) for 12weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral intake placebo(960mg/day) for 12weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Uroflowmetry(Max Flow Rate)</title>
          <description>uroflowmetry(max flow rate) was measured in study visit 1(0 week) and visit 3(12 week).</description>
          <population>per protocol analysis</population>
          <units>m/sec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.65" spread="9.48"/>
                    <measurement group_id="O2" value="17.64" spread="6.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.63" spread="8.96"/>
                    <measurement group_id="O2" value="20.95" spread="9.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in IIEF(International Index of Erectile Function)-Total Domain</title>
        <description>IIEF(International Index of Erectile Function)-total domain(score range: 5-75) was measured in study visit 1(0 week) and visit 3(12 week).
IIEF includes 15 questions and addresses the 5 sub-domains of Erectile function, Intercourse satisfaction, Orgasm function, Sexual desire, and Overall satisfaction.
The IIEF-total domain is the sum of sub-domains. Lower scores indicate severe erectile dysfunction, while higher scores indicate less erectile dysfunction.</description>
        <time_frame>12 weeks</time_frame>
        <population>per protocol analysis</population>
        <group_list>
          <group group_id="O1">
            <title>EFLA400</title>
            <description>Oral intake EFLA400(960mg/day) for 12weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral intake placebo(960mg/day) for 12weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in IIEF(International Index of Erectile Function)-Total Domain</title>
          <description>IIEF(International Index of Erectile Function)-total domain(score range: 5-75) was measured in study visit 1(0 week) and visit 3(12 week).
IIEF includes 15 questions and addresses the 5 sub-domains of Erectile function, Intercourse satisfaction, Orgasm function, Sexual desire, and Overall satisfaction.
The IIEF-total domain is the sum of sub-domains. Lower scores indicate severe erectile dysfunction, while higher scores indicate less erectile dysfunction.</description>
          <population>per protocol analysis</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.83" spread="10.89"/>
                    <measurement group_id="O2" value="41.00" spread="10.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.11" spread="12.04"/>
                    <measurement group_id="O2" value="50.41" spread="12.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Serious and/or other [non-serious] adverse events were not collected/assessed</desc>
      <group_list>
        <group group_id="E1">
          <title>EFLA400(960mg)</title>
        </group>
        <group group_id="E2">
          <title>Placebo(960mg)</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jong-Kwan Park, MD</name_or_title>
      <organization>Clinical Trial Center for Functional Foods; Chonbuk National University Hospital</organization>
      <phone>82-63-276-8284</phone>
      <email>rain@chonbuk.ac.kr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

